secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001689375-25-000049
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada Q3 net loss widens to $44.1M; DMD pipeline on track for data in 2026
----------------------------------------------------------------------------

- Net loss of $44.1M for Q3 2025, compared to $14.0M net loss in Q3 2024; collaboration revenue fell to $1.6M from $19.6M.
- Cash, cash equivalents & marketable securities of $326.8M extended runway into Q3 2027.
- ELEVATE-44-201 cohort 1 data on track for Q2 2026; first patient dosed in ELEVATE-45-201 with cohort 1 data expected mid-2026.
- Filed UK regulatory authorization for ENTR-601-50; plans to submit EU applications in H2 2026.
- Vertex VX-670 (DM1) trial enrollment and dosing on track for completion in H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937525000049/0001689375-25-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937525000049/trda-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001689375-25-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer